SCHEMBL18970375

SCHEMBL18970375

CN(C)Cc1cccc(C(=O)NCc2ccccc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 1/20 0.64
HDAC8 Q9BY41 1/20 0.64
HDAC6 Q9UBN7 1/20 0.64
ALDH1A1 P00352 5/20 0.60
GAA P10253 1/20 0.60
HSD17B10 Q99714 1/20 0.60
PPARG P37231 1/20 0.59
POLB P06746 2/20 0.57
CFD P00746 1/20 0.57
ROCK2 O75116 3/20 0.57
CYP3A4 P08684 2/20 0.57
HTT P42858 3/20 0.56
HPGD P15428 2/20 0.55
EPHX2 P34913 1/20 0.55
NR1H4 Q96RI1 1/20 0.55
CYP2C19 P33261 1/20 0.55
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
KMT2A Q03164 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL308230 0.86 CFD (0.59) HDAC2HDAC8HDAC6PPARGCFD
SCHEMBL23014402 0.86 HDAC2 (0.50) HDAC2HDAC8HDAC6ALDH1A1GAA
SCHEMBL22047184 0.84 PPARG (0.78) HDAC2HDAC8HDAC6ALDH1A1GAA
SCHEMBL11900328 0.84 HDAC6 (0.87) HDAC2HDAC8HDAC6ALDH1A1GAA
SCHEMBL14044800 0.83 HDAC2 (0.69) HDAC2HDAC8HDAC6ALDH1A1GAA
SCHEMBL6175213 0.81 SLC7A5 (0.56) HDAC8HDAC6ROCK2CYP3A4CYP2C19
SCHEMBL6581113 0.81 ALDH1A1 (0.54) ALDH1A1GAAROCK2CYP3A4HTT
SCHEMBL1696365 0.81 HDAC6 (0.66) HDAC2HDAC8HDAC6ALDH1A1GAA
SCHEMBL25718860 0.80 ROCK2 (0.75) ROCK2CYP3A4
SCHEMBL10084687 0.80 NPC1 (0.73) HDAC2HDAC8HDAC6ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166560-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166560-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 HDAC2 1245/4885HDAC8 1022/4885HDAC6 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.